Alkermes plc.(ALKS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,874 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
ALKS Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Alkermes plc. (ALKS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALKS at 45.2/100 on a 32-signal composite quality model, placing it at rank #1,874 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Alkermes plc. reports quarterly revenue of $496.0M, net income of $501.0K, an operating margin of 3.7%. Top institutional holders of ALKS by reported 13-F value include BlackRock, BAKER BROS. ADVISORS, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. ALKS trades on the Nasdaq exchange and files with the SEC under CIK 1520262. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALKS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alkermes plc. directly from SEC EDGAR. Alkermes plc.'s 13F Pro composite quality score has ranged between 45 and 59 since 2026, currently 45.2 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.
Revenue
Q2 2026
$496.0M
Net Income
Q2 2026
$501.0K
Free Cash Flow
Q2 2026
$137.0M
Operating Margin
Q2 2026
3.7%
ROIC
Q2 2026
2.2%
D/E Ratio
Q2 2026
0.86
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-5.2% YoYNet Income
-34.2% YoYOperating Income
-39.6% YoYEPS (Diluted)
-34.1% YoYTotal Assets
+21.0% YoYTotal Debt
Op. Cash Flow
+18.6% YoYFree Cash Flow
+18.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.48B -5.2% | $1.56B -6.4% | $1.66B +49.6% | $1.11B -5.3% | $1.17B +13.0% | $1.04B |
| Net Income | $241.7M -34.2% | $367.1M +3.2% | $355.8M +324.8% | $-158.3M -228.6% | $-48.2M +56.6% | $-110.9M |
| Operating Income | $254.0M -39.6% | $420.6M +1.6% | $414.1M +6901.1% | $-6.1M -106.2% | $97.7M +186.9% | $-112.4M |
| EPS (Diluted) | $1.43 -34.1% | $2.17 +3.3% | $2.10 +316.5% | $-0.97 -234.5% | $-0.29 +58.6% | $-0.70 |
| Total Assets | $2.49B +21.0% | $2.06B -3.8% | $2.14B +8.8% | $1.96B -3.0% | $2.02B +3.8% | $1.95B |
| Total Debt | $0.00 | — | $290.7M -0.9% | $293.3M -0.9% | $295.8M +7.6% | $275.0M |
| Operating Cash Flow | $520.8M +18.6% | $439.1M +9.4% | $401.4M +1807.2% | $21.0M -79.3% | $101.7M +22.8% | $82.8M |
| Free Cash Flow | $480.3M +18.4% | $405.6M +14.8% | $353.3M +2152.8% | $-17.2M -123.4% | $73.7M +81.4% | $40.6M |
Get alerted when ALKS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Alkermes plc. including:
Top Institutional Holders of ALKS
BlackRock, Inc.
$1.5B29,235,739 shBAKER BROS. ADVISORS LP
$524.6M10,012,267 shVANGUARD PORTFOLIO MANAGEMENT LLC
$497.3M9,490,818 shSTATE STREET CORP
$480.0M9,160,575 shVANGUARD CAPITAL MANAGEMENT LLC
$393.7M7,515,025 shPRICE T ROWE ASSOCIATES INC /MD/
$353.0M6,737,328 shRENAISSANCE TECHNOLOGIES LLC
$338.5M6,460,928 shGEODE CAPITAL MANAGEMENT, LLC
$234.7M4,477,876 shDIMENSIONAL FUND ADVISORS LP
$219.8M4,194,873 shDeep Track Capital, LP
$209.6M4,000,000 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $1.5B | 29,235,739 |
| BAKER BROS. ADVISORS LP | $524.6M | 10,012,267 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $497.3M | 9,490,818 |
| STATE STREET CORP | $480.0M | 9,160,575 |
| VANGUARD CAPITAL MANAGEMENT LLC | $393.7M | 7,515,025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $353.0M | 6,737,328 |
| RENAISSANCE TECHNOLOGIES LLC | $338.5M | 6,460,928 |
| GEODE CAPITAL MANAGEMENT, LLC | $234.7M | 4,477,876 |
| DIMENSIONAL FUND ADVISORS LP | $219.8M | 4,194,873 |
| Deep Track Capital, LP | $209.6M | 4,000,000 |
Companies Similar to ALKS
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BIOMARIN PHARMACEUTICAL INC
CORCEPT THERAPEUTICS INC
PTC THERAPEUTICS, INC.
IONIS PHARMACEUTICALS INC
Travere Therapeutics, Inc.
COOPER COMPANIES, INC.
Tarsus Pharmaceuticals, Inc.
SUPERNUS PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put ALKS on your watchlist
Track score changes the day Alkermes plc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALKS a good stock to buy?
13F Pro's AI-powered analysis of Alkermes plc. (ALKS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALKS are available on the ALKS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ALKS is classified as a mid company.
Which hedge funds own ALKS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALKS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alkermes plc.'s investment landscape.